After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...